AC Immune (NASDAQ:ACIU) Rating Lowered to “Hold” at Zacks Research

AC Immune (NASDAQ:ACIU) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Wednesday, Zacks reports.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 20th. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of AC Immune in a report on Wednesday, September 23rd. Finally, HC Wainwright reissued a “buy” rating on shares of AC Immune in a research note on Thursday, September 24th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AC Immune presently has a consensus rating of “Hold” and a consensus price target of $7.50.

AC Immune Stock Performance

Shares of ACIU stock opened at $2.37 on Wednesday. The firm has a market capitalization of $241.20 million, a PE ratio of -4.39 and a beta of 1.56. The firm has a fifty day simple moving average of $2.62 and a two-hundred day simple moving average of $2.74. AC Immune has a 12 month low of $2.03 and a 12 month high of $3.90.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. On average, equities analysts predict that AC Immune will post -0.60 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

Several institutional investors and hedge funds have recently made changes to their positions in the company. AXQ Capital LP purchased a new position in AC Immune during the second quarter worth about $25,000. Arrowstreet Capital Limited Partnership grew its position in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after buying an additional 176,701 shares during the last quarter. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.